Balloon Mold

Other Search Results

Asthma in children and adolescents

Oct 08, 2008 - In This Report

Highlights
Introduction
Causes
Prognosis
Risk Factors
Symptoms
Diagnosis
Treatment
Quick-Relief Medications...
Long-Term Relief Medication...
Other Treatments
Managing Asthma
Resources
References

HEALTH GUIDE REFERENCE FROM A.D.A.M Highlights Drug Warning In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Health care providers need to carefully observe patients for 2 hours after they receive an omalizumab injection. However, because an allergic reaction can occur up to 24 hours after the injection, patients need to know the signs and symptoms of anaphylaxis and how to self-administer emergency treatment. - 0 Comments

If Money Weren't an Issue . . .

Asthma in children and adolescents

PopSugar Rush Ad

Email Collector

Features

Sponsored Content

More on CasaSugar

Fall Award Season